Similarities and Differences Between Small Molecules and Biologics: Examples of Drugs for Alzheimer's Disease

© 2025 by the Author. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Alzheimer’s disease is a neurodegenerative disease with a hidden onset. Existing therapeutic drugs can only delay the progression of the disease and relieve symptoms. Small interfering RNAs show potential for the treatment of Alzheimer’s disease by cleaving mRNA encoding target genes, but many challenges need to be overcome by stably delivering small interfering RNA to the lesions. This paper describes the pathological mechanism of Alzheimer’s disease, existing drug targets, the advantages and challenges of small interfering RNA therapy, research progress in the transblood-brain barrier delivery system, new small interfering RNA delivery system and ongoing clinical trials of Alzheimer’s disease drugs, etc., and strives to provide reference and reference for related research on small interfering RNA therapy for Alzheimer’s disease.

Keywords

Biological small molecules

Drugs for Alzheimer’s disease

Drug research and development

References

[1] Ahn E, Park J, 2025, Molecular Mechanisms of Alzheimer’s Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy. Cells, 14(2): 89.

[2] Scheltens P, Strooper B, Kivipelto M, et al., 2021, Alzheimer’s Disease. The Lancet, 397(10284): 1577–1590.

[3] Zhang J, Zhang Y, Wang J, et al., 2024, Recent Advances in Alzheimer’s Disease: Mechanisms, Clinical Trials and New Drug Development Strategies. Signal Transduct Target Ther, 9(1): 211.

[4] Cummings J, Fox N, 2017, Defining Disease Modifying Therapy for Alzheimer’s Disease. J Prev Alzheimer’ss Dis, 4(2): 109–115.

[5] Wouters O, Vogel M, Feldman W, et al., 2024, Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US. JAMA, 332(24): 2101–2108.

[6] Liu J, Ting J, Al-Azzam S, et al., 2021, Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. Int J Mol Sci, 22(6): 2805.

[7] Pohanka M, 2012, Acetylcholinesterase Inhibitors: A Patent Review (2008–Present). Expert Opinion on Therapeutic Patents, 22(8): 871–886.

[8] Dawood D, Anwar M, 2025, Recent Advances in the Therapeutic Insights of Thiazole Scaffolds as Acetylcholinesterase Inhibitors. European Journal of Medicinal Chemistry, 287: 117331.

[9] Bartus R, Dean R, Beer B, et al., 1982, The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science, 217(4558): 408–414.

[10] Ríos C, Marco-Contelles J, 2019, Tacrines for Alzheimer’s Disease Therapy. III. The PyridoTacrines. European Journal of Medicinal Chemistry, 166: 381–389.

[11] Chang C, Lin C, Lane H, 2020, d-Glutamate and Gut Microbiota in Alzheimer’s Disease. Int J Mol Sci, 21(8): 2676.

[12] Greenamyre J, Maragos W, Albin R, et al., 1988, Glutamate Transmission and Toxicity in Alzheimer’s Disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 12(4): 421–IN4.

[13] Reisberg B, Doody R, Stöffler A, et al., 2003, Memantine in Moderate-to-Severe Alzheimer’s Disease. N Engl J Med, 348(14): 1333–1341.

[14] Schneider L, Sano M, 2009, Current Alzheimer’s Disease Clinical Trials: Methods and Placebo Outcomes. Alzheimer’s Dement, 5(5): 388–397.

[15] Pradeepkiran J, Baig J, Islam M, et al., 2024, Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease. Aging Dis, 16(2): 658–682.

[16] Kang J, Lemaire H, Unterbeck A, et al., 1987, The Precursor of Alzheimer’s Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor. Nature, 325(6106): 733–736.

[17] Sevigny J, Chiao P, Bussière T, et al., 2016, The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease. Nature, 537(7618): 50–56.

[18] Haeberlein S, Aisen P, Barkhof F, et al., 2022, Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimer’ss Dis, 9(2): 197–210.

[19] Cummings J, Zhou Y, Lee G, et al., 2024, Alzheimer’s Disease Drug Development Pipeline: 2024. Alzheimer’ss Dement (N Y), 10(2): e12465.

[20] Alexander G, Knopman D, Emerson S, et al., 2021, Revisiting FDA Approval of Aducanumab. N Engl J Med, 385(9): 769–771.

[21] Rosen J, Jessen F, 2025, Patient Eligibility for Amyloid-Targeting Immunotherapies in Alzheimer’s Disease. Journal of Prevention of Alzheimer’s Disease, 12(4): 100102.

[22] Dyck C, Swanson C, Aisen P, et al., 2023, Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, 388(1): 9–21.

[23] Sims J, Zimmer J, Evans C, et al., 2023, Donanemab in Early Symptomatic Alzheimer’s Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, 330(6): 512–527.

[24] Han G, Priefer R, 2023, A Systematic Review of Various pKa Determination Techniques. International Journal of Pharmaceutics, 635: 122783.

[25] Salminen W, Wiles M, Stevens R, 2019, Streamlining Nonclinical Drug Development Using the FDA 505(b)(2) New Drug Application Regulatory Pathway. Drug Discovery Today, 24(1): 46–56.

[26] Nugent B, Ramamoorthy A, Pippins J, et al., 2025, Confirmatory Evidence Used in Non-Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023. Clin Pharmacol Ther, 117(6): 1627–1631.

[27] Hay M, Thomas D, Craighead J, et al., 2014, Clinical Development Success Rates for Investigational Drugs. Nature Biotechnology, 32(1): 40–51.

[28] Kesselheim A, Sinha M, Avorn J, 2017, Determinants of Market Exclusivity for Prescription Drugs in the United States. JAMA Internal Medicine, 177(11): 1658–1664.

[29] Kulkarni S, Gaikwad V, 2023, Common Chemistry, Manufacturing, and Control Deficiencies in Abbreviated New Drug Applications Assessed by the US Food and Drug Administration: Hurdle to Access Cost-Effective Medicines. Journal of Pharmacological and Toxicological Methods, 123: 107295.

[30] Zhu H, Zhou H, Seitz K, 2009, Chapter 15 - Bioavailability and Bioequivalence. In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR, editors. Developing Solid Oral Dosage Forms. Academic Press, San Diego, 341–364.

[31] Ranjan R, 2025, Development of Complex Generics and Similar Biological Products: An Industrial Perspective of Reverse Engineering. AAPS PharmSciTech, 26(4): 95.

[32] Monga A, Gagan, Jamwal P, et al., 2025, Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications. AAPS PharmSciTech, 26(1): 46.

[33] Cummings J, Aisen P, DuBois B, et al., 2016, Drug Development in Alzheimer’s Disease: The Path to 2025. Alzheimer’s Res Ther, 8: 39.

[34] Rome B, Egilman A, Kesselheim A, 2022, Trends in Prescription Drug Launch Prices, 2008–2021. JAMA, 327(21): 2145–2147.

Previous article in this issue

Next article in this issue